Coherus Biosciences has filed two petitions for inter partes review of Abbvie’s U.S. Patent 9,085,619.  (IPR2017-01008 and IPR2017-01009).  Coherus recently filed four other petitions for inter partes review of the ‘619 patent, as we’ve reported.  Those cases are pending an institution decision.

According to the petitions, the ‘619 patent is drawn to formulations of Humira® (adalimumab).  Humira®, sold by Abbvie, is approved to treat a number of conditions, including rheumatoid arthritis.

These petitions and other PTAB filings on biologic patents are posted on our IPR tracker page.